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Abstract: Nicotinic acid, known as vitamin B3, is an effective lipid lowering drug and 
intense cutaneous vasodilator. This study reports the effect of 2-(1-adamantylthio)nicotinic 
acid (6) and its amide 7 and nitrile analog 8 on phenylephrine-induced contraction of rat 
thoracic aorta as well as antioxidative activity. It was found that the tested thionicotinic 
acid analogs 6-8 exerted maximal vasorelaxation in a dose-dependent manner, but their 
effects were less than acetylcholine (ACh)-induced nitric oxide (NO) vasorelaxation. The 
vasorelaxations were reduced, apparently, in both N
G-nitro-L-arginine methyl ester   
(L-NAME) and indomethacin (INDO). Synergistic effects were observed in the presence of 
L-NAME plus INDO, leading to loss of vasorelaxation of both the ACh and the tested 
nicotinic acids. Complete loss of the vasorelaxation was noted under removal of 
endothelial cells. This infers that the vasorelaxations are mediated partially by 
endothelium-induced NO and prostacyclin. The thionicotinic acid analogs all exhibited 
antioxidant properties in both 2,2-diphenyl-1-picrylhydrazyl (DPPH) and superoxide 
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dismutase (SOD) assays. Significantly, the thionicotinic acid 6 is the most potent 
vasorelaxant with ED50 of 21.3 nM and is the most potent antioxidant (as discerned from 
DPPH assay). Molecular modeling was also used to provide mechanistic insights into the 
vasorelaxant and antioxidative activities. The findings reveal that the thionicotinic acid 
analogs are a novel class of vasorelaxant and antioxidant compounds which have potential 
to be further developed as promising therapeutics. 
Keywords:  1-adamantylthionicotinic acid and derivatives; vasorelaxants; antioxidants; 
nitric oxide; prostacyclin; molecular modeling 
 
1. Introduction 
Nicotinic acid (niacin), also known as vitamin B3, has been used as a vitamin supplement in human 
and animal nutrition [1]. Deficiencies of vitamin B3 result in avitaminoses, which lead to skin diseases 
and nervous disorders [1]. Nicotinic acid is an effective lipid lowering drug and an intense cutaneous 
vasodilator which causes flushing [2,3]. The flushing has been shown to be mediated by nicotinic acid 
or orphan receptor (GPR109A or HM74A or PUMA-G) and to involve the formation of vasodilatory 
prostanoids [4]. Nicotinamide is a derivative of nicotinic acid, and both the amide and acid occur 
naturally, almost exclusively in bound form [1]. Nicotinamide is a known vasodilator [5] which relaxes 
smooth muscle by inhibiting myosin light chain kinase [6]. Nicotinic acid has been used as topical 
vasodilator or skin cream prior to luminous laser treatment [7]. Both nicotinic acid and nicotinamide 
were also used as cosmetic compositions such as lipstick for providing improve skin feel [8].  
Nicotinic acid was introduced into clinical therapy as the first lipid modifying drug [9]. It has been 
used for decades as an effective antidyslipidaemic drug due to its ability to strongly increase the 
plasma HDL cholesterol concentration, but decreasing both LDL and total cholesterol including 
lowering concentration of very low density lipoprotein (VLDL) and plasma triglyceride. Thus, it is 
referred to as a broad spectrum lipid drug [9]. Such events are important therapeutic measures to 
reduce cardiovascular morbidity and mortality [9]. It has been shown that the nicotinic acid reduces 
cardiovascular events in patients with dyslipidemia [2]. However, its clinical use is hindered by 
harmless, but unpleasant side effect, in particular, a strong flussing [2,3]. In recent years, 
pharmacological potential of nicotinic acid has drawn considerable interest [4]. Derivatives of 
nicotinic acid and related compounds e.g. nicorandil (1) [10], nicotinate esters 2, β-picolyl ethers (and 
thioethers) 3 and pyridyl-3-carbinols 4 [11] including nicotinamide adenosine diphosphate (NAD
+) 
[12] have been reported as vasodilators. Moreover, picolyl thioethers also exhibited hypotensive 
activity  as  compared  to  ether  and  carboxyl  or  amide  analogs  [11].  It  was  reported  that                 
5-mercaptopyridine-2-carboxylic acid (5, Figure 1) displayed antihypertensive activity [13].  
Presently, cardiovascular disease is one of the major health problems accounting for enormous 
morbidity and mortality worldwide. Therefore, it is crucial to investigate for new vasoactive 
compounds that affect the functional endothelial cells, which are key regulating cells in the vessel 
wall. To discover novel vasodilators for medicinal applications, our rational molecular design is based 
on the documented activity of nicotinic acid  derivatives  and  related  compounds.  In  this  context,          Molecules 2010, 15                                       
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1-adamantyl-thionicotinic acid analogs 6-8 (Figure 2) are interesting target molecules. The target 
compounds  6-8 were prepared as described previously [14] and evaluated for vasorelaxant and 
antioxidative activities. 
Figure 1. Chemical structure of nicotinic acid derivatives and related compounds 1-5. 
 
 
 
 
 
 
 
2. Results and Discussion 
2.1. Tested compounds 
1-Adamantylthionicotinic acid derivatives 6-8 were obtained [14] from the reaction of nicotinic 
acid, nicotinamide and nicotinonitrile N-oxides with 1-adamantylmercaptan in boiling acetic 
anhydride. The structures of analogs 6-8 was confirmed by IR and 
1H-NMR spectral data and their 
melting points. 
2.2. Vasorelaxant activity 
Effects of thionicotinic acid analogs 6-8 on vascular function of rat thoracic aorta precontracted 
with  L-phenylephrine (PE) were explored under various conditions; in the presence or absence of 
inhibitors, namely, N
G-nitro-L-arginine methyl ester (L-NAME) and indomethacin (INDO) and under 
denuded endothelial cells. In addition, the effects of acetylcholine (ACh) as a positive control, sodium 
nitroprusside (SNP) as a negative control and vehicle; dimethyl sulfoxide (DMSO) also were studied. 
Results confirmed that the vasorelaxation of ACh was related to nitric oxide (NO). The DMSO had no 
effect on induction of vasorelaxations.  
2.2.1. Effect of thionicotinic acid derivatives 6-8 on the vascular function of rat thoracic aorta in the 
presence and absence of L-NAME. 
Thionicotinic acid 6  
The study was performed in the absence and presence of nitric oxide synthase (NOS) inhibitor       
L-NAME (1 mM). It was found that thionicotinic acid analog 6 exerted vasorelaxation in a dose-
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dependent manner (Figure 3, Table 1). Maximal vasorelaxation (Rmax) of analog 6 was 78.7%, while 
ACh produced Rmax of 108.2%showing ED50 of 2.13 × 10
-8 and 4.72 × 10
-7 M, respectively. In the 
presence of L-NAME (1 mM), the dose-response curve of analog 6 was shifted to the right with Rmax of 
47.6% and ED50 of 2.5 × 10
-8 M. While ACh displayed Rmax of 81.6% with ED50 of 4.92 × 10
-7 M. 
This suggested that thionicotinic acid 6 exhibited vasorelaxant activity by partially producing NO from 
the endothelial cells. 
Figure 2.  Chemical  structures  (a)  and  geometrically  optimized  structures  at           
B3LYP/6-31g(d) (b) of thionicotinic acid analogs 6-8. 
 
 
 
 
 
Table 1. Vasorelaxant activity of thionicotinic acid analogs 6-8. 
Compound 
Vasorelaxant activity 
Without L-NAME    With L-NAME (1mM) 
Rmax (%)  ED50 (M)    Rmax (%)  ED50 (M) 
6
a  78.67 ± 0.48  2.13 × 10
-8    47.60 ± 0.83  2.50 × 10
-8 
ACh
a  108.17 ± 1.22  4.72 × 10
-7    81.59 ± 0.63  4.92 × 10
-7 
7
b  77.69 ± 0.47  1.25 × 10
-7    43.72 ± 0.70  2.66 × 10
-7 
ACh
b  109.86 ± 0.65  5.29 × 10
-7    83.54 ± 0.91  5.49 × 10
-7 
8
a  71.64 ± 0.55  2.44 × 10
-7    42.36 ± 0.98  3.05 × 10
-7 
ACh
a  108.17 ± 1.22  4.72 × 10
-7    81.59 ± 0.27  4.92 × 10
-7 
a Data obtained from six experiments; 
b Data obtained from five experiments. 
Thionicotinamide analog 7 
Similar results (Table 1, Figure 4) were observed for thionicotinamide derivative 7 and ACh, which 
exhibited Rmax of 77.7% and 109.9% with ED50 of 1.25 × 10
-7 and 5.29 × 10
-7 M, respectively. In the 
presence of L-NAME (1 mM), the dose-response curve of thionicotinamide 7 and ACh was shifted to 
the right.  Rmax of derivative 7  and ACh was found to be 43.7% and 83.5%, whereas ED50 were        
2.66 × 10
-7 and 5.49 × 10
-7 M, respectively. 
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Figure 3. Effect of 6 on the vascular function of rat thoracic aorta in the presence of          
L-NAME (1 mM) compared with ACh.  
 
 
 
 
 
Data represented as mean ± s.e.m. of six experiments, each performed in duplicate. *p < 0.05, ACh 
versus ACh+L-NAME, **p < 0.05, ACh versus 6, + p < 0.05, 6 versus 6 + L-NAME. 
Figure 4. Effect of 7  on the vascular function of rat thoracic aorta in the presence of          
L-NAME (1 mM) compared with ACh.  
 
 
 
 
 
 
Data represented as mean ± s.e.m. of five experiments, each performed in duplicate. *p < 0.05, 
ACh versus ACh+L-NAME, **p < 0.05, ACh versus 7, + p < 0.05, 7 versus 7 + L-NAME. 
Thionicotinonitrile analog 8 
Similarly, thionicotinonitrile analog 8 displayed vasorelaxant effect (Table 1, Figure 5) with Rmax of 
71.6% and ED50 of 2.44 × 10
-7 M, whereas Rmax of ACh was 108.2% with ED50 of 4.72 × 10
-7 M. The 
dose-response curve of analog 8 was shifted to the right in the presence of L-NAME (1 mM) showing 
Rmax and ED50 of 42.4% and 3.05 × 10
-7 M, respectively. The Rmax of ACh was reduced to 81.6% with 
ED50 of 4.92 × 10
-7 M. 
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Figure 5. Effect of 8 on the vascular function of rat thoracic aorta in the presence of          
L-NAME (1 mM) compared with ACh.  
 
 
 
 
 
Data represented as mean ± s.e.m. of six experiments, each performed in duplicate. *p < 0.05, ACh 
versus ACh+L-NAME, **p < 0.05, ACh versus 8, + p < 0.05, 8 versus 8 + L-NAME. 
2.2.2. Effect of endothelial cells on vasorelaxant activity of thionicotinic acid derivatives 6-8 
The activity was evaluated comparing with Ach with and without intact endothelial cells. The 
results (Table 2) showed that the vasorelaxation of all tested analogs 6–8 was abolished under removal 
of the endothelial cells. An example of dose response curve such as analog 6 is shown (Figure 6). The 
similar result was noted for the control; ACh. This confirmed that the vasorelaxant of analogs 6–8 was 
mediated through endothelial producing NO. 
Table 2. Effect of endothelial cells on vascular effect of nicotinic acid analogs 6-8. 
 
 
 
 
 
a +et: in the presence of endothelial cells; 
b -et: in the absence of endothelial cells; 
c Data obtained 
from five experiments; 
d Data obtained from six experiments. 
 
Compound 
Vasorelaxant  activity 
+et
 a   −et
 b 
Rmax (%)  ED50 (M)    Rmax (%)  ED50 (M) 
6
c  78.18 ± 0.79  6.64 × 10
-8   0  − 
ACh
c  104.89 ± 1.33  2.66 × 10
-7    7.11 ± 0.35  3.13 × 10
-7 
7
d  75.19 ± 0.59  1.05 × 10
-7   0  − 
ACh
d  103.45 ± 1.12  3.35 × 10
-7    7.47 ± 0.15  3.13 × 10
-7 
8
d  71.92 ± 0.52  3.82 × 10
-7   0  − 
ACh
d  103.45 ± 1.12  3.35 × 10
-7    7.47 ± 0.15  3.13 × 10
-7 
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
140
log [Substance] (M)
%
 
R
e
l
a
x
a
t
i
o
n ACh
ACh+L-NAME
SP-4
SP-4+L-NAME
*
*
**
+ +
+
* *
** **
8+L-NAME+
8**
ACh
ACh+L-NAME
SP-4
SP-4+L-NAME
*
*
**
+ +
+
* *
** **
8+L-NAME+
8**Molecules 2010, 15                                       
 
 
204
Figure 6. Effect of 6 and ACh on the vascular function of rat thoracic aorta under removal 
of endothelium (-et) compared with intact endothelium (+et). 
 
 
 
 
 
 
Data represented as mean ± s.e.m. of five experiments, each performed in duplicate. *p < 0.05, 
ACh (+et) versus ACh (-et), **p < 0.05, ACh (+et) versus 6 (+et), + p < 0.05, 6 (+et) versus 6 (-et). 
2.2.3. Effect of derivatives 6-8 on the vascular function of rat thoracic aorta in the presence of cyclo-
oxygenase inhibitor (INDO)  
The vasorelaxant activity of analogs 6-8 was investigated in the presence of INDO (1 mM), 
compared with L-NAME (1 mM) and L-NAME plus INDO. The results (Table 3) revealed that 
experiments carried out with L-NAME or INDO showed significant reductions of vasorelaxation 
(Figure 7) in a dose–dependent manner.   
 
Table 3. Effect of inhibitors on vascular effect of nicotinic acid analogs 6-8. 
Compound 
Vasorelaxant  activity 
−Inhibitor
a  +L-NAME (1mM)  +INDO (1mM)  +L-NAME (1mM) 
+INDO (1mM) 
Rmax (%)  ED50 (M)  Rmax (%)  ED50 (M)  Rmax (%)  ED50 (M)  Rmax (%)  ED50 (M) 
ACh
b  121.7 ± 1.44  9.99 × 10
-7  81.34 ± 0.77  5.44 × 10
-7  68.78 ± 0.92  4.58 × 10
-7 0  − 
6
b  77.67±0.66  1.78 × 10
-8  47.44 ± 0.44  3.55 × 10
-8  46.05 ± 0.26  7.17 × 10
-8 0  − 
7
b  76.93±0.56  1.23 × 10
-7  43.22 ± 0.66  3.88 × 10
-7  36.49 ± 0.60  6.34 × 10
-7 0  − 
8
b  71.47±0.42  2.05 × 10
-7  42.10 ± 0.65  3.43 × 10
-7  37.63 ± 0.62  6.14 × 10
-7 0  − 
SNP
c  120.81±1.18  3.16 × 10
-7  116.70 ± 1.30  3.17 × 10
-7  112.93 ± 0.61  3.16 × 10
-7 104.98±1.41  3.17×10
-7 
a -Inhibitor: in the absence of L-NAME or INDO; 
b Data obtained from five experiments; 
c Data obtained 
from six experiments. 
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Figure 7. Effect of 6 on the vascular function of rat thoracic aorta in the presence of INDO 
compared with L-NAME and with L-NAME plus INDO. 
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Data represented as means ± s.e.m. of five experiments, each performed in duplicate. *p < 0.05, 6 
versus 6 +     L-NAME, **p < 0.05, 6 versus 6 + INDO, + p < 0.05, 6 versus 6 + L-NAME + INDO. 
 
The inhibitory effect of INDO was comparable to that of L-NAME; as noted from the fact that  
thionicotinic acid analog 6 showed Rmax of 47.4% and 46.1%, respectively. However, the antagonistic 
effects of INDO were stronger than those of L-NAME, as evidenced by the fact that thionicotinamide 
analog  7 and thionicotinonitrile 8 showed comparable Rmax of 36.5% and 37.6%, respectively. 
Moreover, significant reductions of Rmax were more pronounced in the presence of L-NAME plus 
INDO. Under such conditions it was found that the vasorelaxation effects of the tested analogs 6-8 and 
ACh were abolished. However, no significant change was observed by the SNP. The results confirmed 
that the analogs 6-8 elicited partial vasorelaxation via endothelial cells producing NO and prostacyclin 
(PGI2). 
The studies have demonstrated that all the tested analogs; 2-(1-adamantylthio)nicotinic acid (6), its 
amide 7 and nitrile 8 derivatives exhibited maximal vasorelaxation in a dose-dependent manner, even 
though the vasorelaxations are less than those produced by the ACh.  Such vasorelaxations are elicited 
by partial NO production from functional endothelial cells, which is observed by a significant 
reduction of the activity in the presence of L-NAME (Table 1). The 2-(1-adamantylthio)nicotinic acid 
(6) displayed the highest vasorelaxation with Rmax of 78.7%, whereas the thionicotinamide (7) 
exhibited comparable Rmax of 77.7%. The lowest vasorelaxant activity was noted for 2-(1-
adamantylthio) nicotinonitrile (8) showing Rmax of 71.6%. Significantly, the thionicotinic acid analog 6 
exerts immediate vasorelaxation with ED50 of 21.3 nM (Figure 3). This is presumably due to the fact 
that the nicotinic acid analog 6 has higher affinity for the receptor than the thionicotinamide 7. Thus, 
the nicotinic acid 6 is the most potent vasorelaxant. Moreover, the vasorelaxant activities of the tested 
analogs 6–8 were all abolished by the removal of functional endothelial cells (Table 2, Figure 6). This 
confirms that the vasorelaxation of analogs 6–8 is modulated via NO production by endothelial cells. 
In fact, ACh involves vasorelaxation by mediating NO, PGI2 and endothelium-derived hyperpolarizing 
factor [15–17]. Thus, the experiments were designed and conducted in the presence of cyclooxygenase 
inhibitor (INDO, 1 mM) compared with L-NAME (1 mM). The results (Table 3) show that the 
vasorelaxation of the tested compounds (6–8) and ACh (Figure 7) is significantly reduced in the dose-Molecules 2010, 15                                       
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dependent manner when compared to that of in the presence of L-NAME. In particular, the 
antagonistic effects of INDO were stronger than L-NAME for analogs 7 and 8. Significant reductions 
of Rmax were profoundly observed in the presence of L-NAME plus INDO which lead to complete loss 
of the activity of the tested compounds and ACh. However, there was no significant change of Rmax 
produced by the SNP. The data support that the thionicotinic acid and derivatives (6-8) exhibit 
vasorelaxation by partial synthesis of NO and PGI2 by functional endothelial cells. The former was 
inhibited by L-NAME, and the latter was inhibited by INDO. It was reported that nicotinic acid itself 
exerted vasorelaxation via mediation of prostaglandin release from vascular function [18,19]. So far, 
vasorelaxation of the thionicotinic acid analogs 6-8 has never been reported in the literature. It is 
known that NO is an important signaling molecule implicated in cardiovascular function such as 
vascular tone, whereas PGI2 is a powerful vasorelaxants and antioxidant. PGI2 is clinically used for 
treatment of pulmonary hypertension and portopulmonary hypertension [20]. 
2.3. Antioxidative activity 
The antioxidative activity of thionicotinic acid derivatives 6-8 was tested using the 2,2-diphenyl-1-
picrylhydrazyl (DPPH) and superoxide dismutase (SOD) assays. The results (Table 4) showed that 
thionicotinic acid 6 was the most potent antioxidant showing 33.20% radical scavenging activity 
(DPPH) at 333.33 μg/mL, whereas thioamide 7  and thionitrile 8 exerted weak activity (0.57 and 
0.30%, respectively).  
The role of NO related to superoxide radical was reported in many studies [21]. Thus, the SOD 
activity of the thioderivatives 6-8 was tested. It was found that the analogs 6-8 displayed comparable 
SOD activity with 15.40–17.31% nitro blue tetrazolium (NBT) inhibition, the thionitrile 8 being the 
strongest antioxidant. 
Table 4. Antioxidative activities of analogs 6-8. 
Compound  % DPPH radical scavenging activity
a  % NBT inhibition
b 
6  33.20 15.40 
7  0.57 15.45 
8  0.30 17.31 
a Concentration of 333.33 μg/mL  was used in the assay. α-Tocopherol was used as a positive control.  
b Concentration of 300 μg/mL was used in the assay. Native SOD (4140 U/mg) from bovine erythrocytes was 
used as a standard. 
2.4. Molecular modeling of vasorelaxant and antioxidative activities 
Previous efforts to elucidate the structure-activity relationship of both vasorelaxant and 
antioxidative activities were purely based on chemical intuitions on the substituent effects of a series 
of compounds [22]. In this study, the structure-activity relationship [23–29] of such activities were 
discerned in a quantitative manner as provided by molecular descriptors derived from density 
functional theory (DFT) calculation at the B3LYP/6-31g(d) level. 
The energy gap of highest occupied molecular orbital (HOMO) and lowest unoccupied molecular 
orbital (LUMO) represents an important stability index [30–32] for molecules where high HOMO-Molecules 2010, 15                                       
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LUMO gap suggests that the compound is highly stable and is inferred to be relatively inert and less 
reactive. On the other hand, compounds with low HOMO-LUMO gap are less stable and are therefore 
more reactive. Such parameter is therefore suitable for assessing the kinetics of vasorelaxant activity as 
provided by ED50. The HOMO-LUMO gap of all the analogs (0.1605-0.1837) was significantly 
smaller than that of Ach (0.2800) (Table 5). This suggests that the thionicotinic acid analogs are more 
chemically and kinetically reactive than ACh as the analogs exhibited lower HOMO-LUMO energy 
gaps than ACh. 
Table 5. Calculated molecular descriptors derived from B3LYP/6-31g(d) as correlated 
with the vasorelaxant ED50. 
Compound Dipole  moment 
(Debye) 
IP  
(eV) 
HOMO-LUMO gap  
(eV) 
ED50  
(M) 
6  2.4098 0.2184  0.1605  2.13×10
-8 
7  3.6920 0.2265  0.1837  1.25×10
-7 
8  4.8092 0.2285  0.1669  2.44×10
-7 
ACh 13.1100  0.3976  0.2800  4.72×10
-7 
Correlation 
with ED50 
0.9594 0.9038  0.8879   
One of the commonly used parameters for assessing the relative antioxidative activity is the 
ionization potential (IP) [33] which essentially measures the electron transferring ability between the 
antioxidant and radical. IP is typically calculated by taking the difference in energy of a neutral and 
anionic species of the molecule of interest. To save computational cost, an alternative approach for 
deriving the IP value can be semi-quantitatively estimated from the negative value of HOMO as 
proposed by Koopman’s theorem. As the Koopman’s theorem was originally stated to be valid for 
Hartree-Fock (HF) theory, previous work has shown that a linear correlation exists between the 
experimental IPs for nine monosubstituted benzene derivatives with both the HF HOMO energies and 
the DFT HOMO energies [34,35]. Such result supports the use of DFT HOMO energy as a relative 
measure of IP for the thionicotinic acid analogs. 
The DPPH radical scavenging activity of the analogs exhibited a negative correlation of −0.9826 
with their estimated IP values (Table 6). The result revealed that 6 was the most potent DPPH radical 
scavenger with an activity of 33.20% while the least potent DPPH radical scavenger was 8. Previous 
efforts had demonstrated that the relative antioxidative activity of a compound can be estimated from 
quantum chemical calculations [36–41]. IP was used as a relative measure of the radical scavenging 
activities of the thionicotinic acid analogs where low IP value is an indicator of good radical 
scavenging activity as the antioxidant has a higher probability of losing an electron to scavenge the 
radical. The experimental results correlated well with the calculated parameter where the best radical 
scavenger, 6, also exhibited the lowest IP (0.2184) while the poorest radical scavenger, 8, also had the 
highest IP (0.2285). 
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Table 6. Calculated molecular descriptors derived from B3LYP/6-31g(d) as correlated 
with the antioxidative activities. 
Compound Dipole  moment 
(Debye) 
IP  
(eV) 
HOMO-LUMO gap  
(eV) 
DPPH  
(%) 
NBT  
(%) 
6  2.4098 0.2184  0.1605  33.20  15.40 
7  3.6920 0.2265  0.1837  0.57  15.45 
8  4.8092 0.2285  0.1669  0.30  17.31 
Correlation 
with DPPH 
-0.8885 -0.9826  -0.7086     
Correlation 
with NBT 
0.8575 0.6748  -0.2276     
 
The SOD activity of the analogs as elucidated by NBT photoreduction provided moderate 
correlation of 0.6748 with the calculated IPs while strong correlation of 0.8575 was observed with the 
dipole moments (Table 6). Results for the latter suggest that electron-withdrawing moiety was crucial 
for the SOD activity as analog 8 possessed the highest dipole moment (4.8092) while exhibiting the 
greatest NBT photoreduction (17.31% inhibition). The opposite is true for the analogs as electron-
donating moeity was found to be crucial for DPPH radical-scavenging activity. In particular, analog 6 
with low dipole moment (2.4098) provided good DPPH radical-scavenging  activity  (33.20%).           
As dipole moment accounts for the asymmetric distribution of charges in a molecule, therefore analogs 
with high dipole moment suggests that there exists a higher degree of charge localization. Of the three 
analogs, 8 possessed the highest dipole moment and also the highest degree of asymmetric charge 
distribution. 
3. Conclusions 
This investigation discloses novel vasorelaxants and antioxidants represented by 2-(1-
adamantylthio)nicotinic acid (6) and its amide 7 and nitrile analog 8. The thionicotinic acid 6 is the 
most potent vasorelaxant and antioxidant (as discerned from DPPH assay). Significantly, the 
thionicotinic acid 6 exhibits immediate vasorelaxation with a nanomolar ED50. The vasorelaxants are 
mediated via endothelium producing NO and PGI2. Molecular modeling analysis revealed that dipole 
moment is a useful molecular descriptor for assessing the vasorelaxant and antioxidative activities. 
Vasorelaxant ED50 was demonstrated to be well correlated with the calculated HOMO-LUMO energy 
gap and that the IP was a useful theoretical parameter for assessing the antioxidative activities. The 
findings show potential development of such thionicotinic acid as promising therapeutics. 
4. Experimental 
4.1. General 
Melting points were determined on an Electrothermal melting point apparatus (Electrothermal 
9100) and are uncorrected. 
1H-NMR spectra were recorded on a Bruker AM 400 instrument with a Molecules 2010, 15                                       
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400/100 MHz operating frequency using CDCl3 or DMSO-d6 solution with tetramethylsilane as an 
internal standard. Infrared spectra (IR) were obtained on a Perkin Elmer System 2000 FTIR. Column 
chromatography was carried out using silica gel 60 (0.063–0.200 mm). Thin layer chromatography 
(TLC) was performed on silica gel 60 PF254 (cat. No. 7747 E., Merck). Solvents were distilled prior to 
use. Chemicals for the synthesis were of analytical grade. Reagents for assays were as follows: PE 
hydrochloride, SNP, L-NAME, ACh, ketamine hydrochloride, INDO, α-tocopherol, DPPH and bovine 
erythrocyte SOD were obtained from Sigma Chemical Co. (USA). DMSO was purchased from Fluka. 
Tested compounds were dissolved in DMSO, then the solutions were further diluted with normal 
saline. 
4.2. Tested compounds 6-8 
The tested compounds were 2-(1-adamantylthio)nicotinic acid (6), 2-(1-adamantylthio)- 
nicotinamide (7) and 2-(1-adamantylthio)nicotinonitrile (8). They were prepared as previously 
described [14] and characterized as follows: compound 6: 
1H-NMR (DMSO-d6): δ2.22-1.73 (m, 15H, 
1-Adm), 7.18 (dd, 1H, J = 7.78, 4.82 Hz, H-5), 8.06 (d, 1H, J = 7.78 Hz, H-4), 8.56 (d, 1H, J = 4.82 
Hz, H-6); compound 7: 
1H-NMR (CDCl3): δ2.13-1.70 (m, 15H, 1-Adm), 6.60 (br, CONH2), 7.18 (dd, 
1H,  J = 7.21, 4.72 Hz, H-5), 8.18 (dd, 1H, J = 7.21, 1.81 Hz, H-4), 8.53 (dd, 1H, J = 4.72, 1.81 Hz,  
H-6) and compound 8: 
1H-NMR (CDCl3): δ2.25-1.75 (m, 15H, 1-Adm), 7.08 (dd, 1H, J = 7.21, 4.72 
Hz, H-5), 7.80 (dd, 1H, J = 7.21, 1.81 Hz, H-4), 8.58 (dd, 1H, J = 4.72, 1.81 Hz, H-6). 
4.3. Vasorelaxant assay 
4.3.1. Isometric tension measurements 
The protocols for handling animals were approved by the Animal Care Committee at the 
Srinakharinwirot University and done at the National Laboratory Animal Centre, Mahidol University. 
Male Sprague-Dawley rats (170-250 g) were anesthetized with intraperitoneal ketamine hydrochloride 
(0.05 mL/kg). The thoracic aorta was quickly removed to cold Kreb-Henseleit buffer containing (mM): 
118 NaCl; 4.7 KCl; 1.2 KH2PO4; 1.2 MgSO4·7H2O; 11.0 (+)-glucose; 25.0 NaHCO3; and   
2.5 CaCl2·2H2O, pH 7.4, aerated with 95% O2, 5% CO2. After removed debris tissue, the vessel was 
cut into rings, each 2-3 mm-long and hanged in the organ bath containing Kreb-Henseleit solution at 
37 °C, aerated with 95% O2, 5% CO2 and also connected to a force-displacement transducer (Model 
MLTO50 Force transducer Range: 50, P.R. China) and equilibrated for 50-60 min under a 1 g resting 
tension. During an incubation period, the Kreb-Henseleit solution was changed every 20 min. After the 
incubation period, the maximal contraction of the rings was determined with high dose of PE (10
-5 M) 
and then washed 5 times until resting tension was recovered. Isometric tension [42,43] was recorded 
by Macintosh MacLab 4E AD Instrument connected to computer hard drive. The endothelial intact 
was examined using high dose of ACh (10
-5 M) at a level of submaximal tension. If the relaxation 
response to ACh was less than 80%, the ring would be discarded. Then, the ring was washed 5 times to 
remove the residue of ACh. The vessel was again equilibrated for 50-60 min and the responses of 
vessel were conducted by the following protocols. Submaximal contraction was induced using PE  
(10
-7  M), then cumulative dose-response curves to the agonists (10
-9-10
-4 M). Finally, the dose-Molecules 2010, 15                                       
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response curve of SNP was performed in order to test the functional vessel. With inhibitors (L-NAME 
or INDO) or vehicle, the vessels were pretreated with such compounds prior to submaximal 
contraction with PE then determined the endothelial response to the tested compounds. After each 
cumulative dose-response curve, the thoracic aorta preparation was washed and equilibrated for 50-60 
min before employing further dose-response curve of tested compounds. 
4.3.2. Statistical analyses 
The unpaired two-tailed Student’s t test and one-way ANOVA were used in the statistical analysis 
when appropriate. Post-hoc comparisons of individual groups were conducted using the Tukey-Kramer 
test. The ED50 values for the vasorelaxants were deduced using nonlinear regression analyses 
(GraphPad Prism 4, GraphPad Software Inc., USA). A p-value less than 0.05 was considered 
significant. The data were expressed as mean ± s.e.m. for the number of animals. 
4.4. Antioxidative assay 
Two assays; DPPH and SOD were used. The antioxidative activity of the tested compounds was 
elucidated by the DPPH radical scavenging assay [44]. When DPPH (a stable purple color) reacts with 
an antioxidant, it is reduced to yield a light-yellow colored diphenylpicrylhydrazine. Color changes 
can be spectrophotometrically measured. In this study, experiment was initiated by preparing 0.2 mM 
solution of DPPH in methanol. One mL of this solution was added sample solution (1 mg/mL 
dissolved in methanol, 0.5 mL). After 30 min, absorbance was measured at 517 nm and the percentage 
of radical scavenging activity was calculated from the following equation: 
% Radical scavenging = (1-Abs.sample/Abs.cont) × 100 
where Abs.cont is the absorbance of the control reaction and Abs.sample is the absorbance in the 
presence of sample. 
The SOD activity was assayed by measuring inhibition of the photoreduction of NBT [45]. The 
indirect assay is comprised of several reactions: the photochemically excited riboflavin was first 
reduced by methionine into a semiquinone, which donated an electron to oxygen to form the 
superoxide source. The superoxide readily converted NBT into a purple formazan product. In this 
regard, the SOD activity was inversely related to the amount of formazan formation. 
4.5. Molecular modeling analysis 
The molecular structures of the thionicotinic acid analogs were drawn using GaussView, version 
3.09 [46]. Full geometry optimization was performed without symmetry constraints under Gaussian 
03W [47] at the density functional theory using the Becke's three-parameter Lee-Yang-Parr (B3LYP) 
functional and 6-31g(d) basis set. The following molecular descriptors were derived from the low 
energy conformer: dipole moment, energies of HOMO and LUMO. The energy gap of HOMO and 
LUMO was then calculated by taking their difference. 
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